CPRX catalystpharma.com: Enterprise Value to Sales Volume

Catalyst Pharmaceuticals, Inc. (CPRX) - corporate logo

Catalyst Pharmaceuticals (CPRX) is integrating ESG principles into the production of neurological drugs to ensure ethical testing. Its monopoly status in the treatment of muscle pathologies allows the company to exercise significant pricing power. The current EV/Sales ratio reflects the business valuation trend, where the 5196.04 metric determines this level. The hyper-profitable sales stage of innovative treatments is restoring mobility to patients with Lambert-Eaton syndrome.

Catalyst Pharmaceuticals Inc - CPRX EV/Sales Multiple (period 11/23/2025 - 07/25/2026)

CPRX (Catalyst Corp): analytical breakdowns and indicator data

Fundamental company valuation:CPRX - Catalyst Pharmaceuticals
Product sample of Catalyst Pharmaceuticals Inc

This indicator determines the enterprise value of the entire business, including net debt, and compares it to sales volume to identify the degree of asset overvaluation. By analyzing the enterprise value-to-revenue trend, an investor can see the monetization efficiency of Catalyst Pharmaceuticals (CPRX) patents for rare neuromuscular disease therapies, which allows for an assessment of the company's fundamental stability amid price fluctuations.

Competitor analysis for Catalyst Pharmaceuticals

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|DNLI (Denali Therapeutics Inc.) - Enterprise Value to Sales Volume|Harmony Corp - EV/Sales Multiple|BHVN: Enterprise Value-to-Revenue Ratio|AMLX: EV/Sales Multiple|TRVI: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio Praxis Medicines|Enterprise Value-to-Revenue Multiple Anavex AVXL|Enterprise Value-to-Revenue Ratio CeriBell Corp (CBLL)|Enterprise Value-to-Revenue Coefficient PRTA|EV/Sales Multiple ALEC (Alector)|Annexon (ANNX) - Enterprise Value-to-Revenue Multiple|OMER - Enterprise Value-to-Revenue Ratio|NGNE (Neurogene) - Company Value to Revenue Ratio|ACIU: EV/Sales Multiple|VYGR - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Neumora Therapeutics, Inc.|Company Value to Revenue Ratio SCLX (Scilex)|Company Value to Revenue TVGN (Tevogen Bio)|EV/Sales Multiple Alpha Cognition Inc (ACOG)|EV/Sales Multiple CGTX (cogrx.com)|Total Company Value-to-Revenue Ratio Inhibikase Pharma (IKT)|SAVA: Company Value to Revenue|Total Company Value-to-Revenue Ratio Assertio ASRT|COYA (coyatherapeutics.com) - Company Value to Revenue|Company Value to Revenue Ratio VTGN|OVID (Ovid Therapeutics) - EV/Sales Multiple|Acumen Pharmaceuticals, Inc (ABOS) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio CervoMed, Inc. (CRVO)|ATHE - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple CLNN (Clene Inc.)|Total Company Value-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Relmada Corp|ANVS (Annovis Bio, Inc.) - Company Value to Revenue|Grace Tx (GRCE) - EV/Sales Multiple|Company Value to Revenue AIFF|EV/Sales Multiple anewmeds.com|Enterprise Value-to-Revenue Ratio NeuroSense Therapeutics (NRSN)|RVPH (Reviva Pharmaceuticals Holdings) - Business Value to Revenue|MetaVia - Company Value to Revenue|NRXS: Company Value to Revenue Ratio|Helius Medical Technologies, Inc. - EV/Sales Multiple|PASG: Enterprise Value-to-Revenue Ratio|Neuphoria (NEUP) - Enterprise Value-to-Revenue Ratio|Minerva Neurosciences - Business Value to Revenue|ATHA (Athira Pharma, Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple addextherapeutics.com ADXN|Company Value to Revenue ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Business Value to Revenue|EV/Sales Multiple PTIX (Protagenic)|EV/Sales Multiple pasitheaclinics.com KTTA|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE